CoreCap Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

CoreCap Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$48.8K	Hold	11,820	–	–	﹤0.01%	1418
2026 Q2	$43.4K	Sell	11,820 -1,000	-8%	-$3.33K	﹤0.01%	1470
2026 Q1	$39.4K	Buy	12,820 +234	+2%	+$904	﹤0.01%	1407
2025 Q4	$51.5K	Buy	12,586 +766	+6%	+$3.79K	﹤0.01%	1323
2025 Q3	$57.7K	Hold	11,820	–	–	﹤0.01%	1256
2025 Q2	$59.8K	Buy	+11,820	New	+$58.1K	﹤0.01%	1173
2024 Q2	–	Sell	-26	Closed	-$259	–	2386
2024 Q1	$259	Buy	+26	New	+$290	﹤0.01%	2391

Other funds holding RXRX

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

Values First Advisors Gray, Tennessee $213M AUM 20.51% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return

Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $252M AUM 40.97% 1-Year Est. Return

Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return

Axxcess Wealth Management Carlsbad, California $2.44B AUM 16.42% 1-Year Est. Return

CoreCap Advisors's RXRX Position: Q3 2026 in Review

CoreCap Advisors held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 11,820 shares worth $48.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1418.

CoreCap Advisors first reported a position in RXRX in Q1 2024 and has held it in 7 quarters since. The position peaked at $59.8K in Q2 2025. 50 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

CoreCap Advisors held 11,820 shares of Recursion Pharmaceuticals worth $48.8K as of Q3 2026.
CoreCap Advisors left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
Recursion Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #1418 holding.
CoreCap Advisors first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
CoreCap Advisors's Recursion Pharmaceuticals position peaked at $59.8K in Q2 2025.
50 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.